Literature DB >> 25297630

CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

David R Soto-Pantoja1, Masaki Terabe2, Arunima Ghosh1, Lisa A Ridnour3, William G DeGraff3, David A Wink3, Jay A Berzofsky2, David D Roberts4.   

Abstract

Although significant advances in radiotherapy have increased its effectiveness in many cancer settings, general strategies to widen the therapeutic window between normal tissue toxicity and malignant tumor destruction would still offer great value. CD47 blockade has been found to confer radioprotection to normal tissues while enhancing tumor radiosensitivity. Here, we report that CD47 blockade directly enhances tumor immunosurveillance by CD8(+) T cells. Combining CD47 blockade with irradiation did not affect fibrosarcoma growth in T cell-deficient mice, whereas adoptive transfer of tumor-specific CD8(+) T cells restored combinatorial efficacy. Furthermore, ablation of CD8(+) T cells abolished radiotherapeutic response in immunocompetent syngeneic hosts. CD47 blockade in either target cells or effector cells was sufficient to enhance antigen-dependent CD8(+) CTL-mediated tumor cell killing in vitro. In CD47-deficient syngeneic hosts, engrafted B16 melanomas were 50% more sensitive to irradiation, establishing that CD47 expression in the microenvironment was sufficient to limit tumor radiosensitivity. Mechanistic investigations revealed increased tumor infiltration by cytotoxic CD8(+) T cells in a CD47-deficient microenvironment, with an associated increase in T cell-dependent intratumoral expression of granzyme B. Correspondingly, an inverse correlation between CD8(+) T-cell infiltration and CD47 expression was observed in human melanomas. Our findings establish that blocking CD47 in the context of radiotherapy enhances antitumor immunity by directly stimulating CD8(+) cytotoxic T cells, with the potential to increase curative responses. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25297630      PMCID: PMC4253868          DOI: 10.1158/0008-5472.CAN-14-0037-T

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  CD47(high) expression on CD4 effectors identifies functional long-lived memory T cell progenitors.

Authors:  Vu Quang Van; Marianne Raymond; Nobuyasu Baba; Manuel Rubio; Keiko Wakahara; Santos A Susin; Marika Sarfati
Journal:  J Immunol       Date:  2012-03-28       Impact factor: 5.422

2.  Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.

Authors:  D Kim; J Wang; S B Willingham; R Martin; G Wernig; I L Weissman
Journal:  Leukemia       Date:  2012-05-30       Impact factor: 11.528

3.  Interactions between CD47 and thrombospondin reduce inflammation.

Authors:  Laurence Lamy; Arnaud Foussat; Eric J Brown; Paul Bornstein; Michel Ticchioni; Alain Bernard
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

4.  Cutting edge: CD47 controls the in vivo proliferation and homeostasis of peripheral CD4+ CD25+ Foxp3+ regulatory T cells that express CD103.

Authors:  Vu Quang Van; Jinane Darwiche; Marianne Raymond; Sylvie Lesage; Salim Bouguermouh; Manuel Rubio; Marika Sarfati
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

5.  A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.

Authors:  S Matsui; J D Ahlers; A O Vortmeyer; M Terabe; T Tsukui; D P Carbone; L A Liotta; J A Berzofsky
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

6.  Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.

Authors:  Daniel W Vermeer; William C Spanos; Paola D Vermeer; Annie M Bruns; Kimberly M Lee; John H Lee
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

7.  CD47 deficiency confers cell and tissue radioprotection by activation of autophagy.

Authors:  David R Soto-Pantoja; Thomas W Miller; Michael L Pendrak; William G DeGraff; Camille Sullivan; Lisa A Ridnour; Mones Abu-Asab; David A Wink; Maria Tsokos; David D Roberts
Journal:  Autophagy       Date:  2012-08-09       Impact factor: 16.016

8.  Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.

Authors:  Justin B Maxhimer; David R Soto-Pantoja; Lisa A Ridnour; Hubert B Shih; William G Degraff; Maria Tsokos; David A Wink; Jeff S Isenberg; David D Roberts
Journal:  Sci Transl Med       Date:  2009-10-21       Impact factor: 17.956

9.  Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.

Authors:  Andrea M Henle; Courtney L Erskine; Linda M Benson; Raphael Clynes; Keith L Knutson
Journal:  J Immunol       Date:  2012-11-23       Impact factor: 5.422

10.  Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system.

Authors:  Tadashi Yokosuka; Kan Takase; Misao Suzuki; Yohko Nakagawa; Shinsuke Taki; Hidemi Takahashi; Takehiko Fujisawa; Hisashi Arase; Takashi Saito
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

View more
  96 in total

1.  CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation.

Authors:  Thomas W Miller; David R Soto-Pantoja; Anthony L Schwartz; John M Sipes; William G DeGraff; Lisa A Ridnour; David A Wink; David D Roberts
Journal:  J Biol Chem       Date:  2015-08-26       Impact factor: 5.157

2.  Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.

Authors:  Zhenyu Xiao; Haniee Chung; Babak Banan; Pamela T Manning; Katherine C Ott; Shin Lin; Benjamin J Capoccia; Vijay Subramanian; Ronald R Hiebsch; Gundumi A Upadhya; Thalachallour Mohanakumar; William A Frazier; Yiing Lin; William C Chapman
Journal:  Cancer Lett       Date:  2015-02-23       Impact factor: 8.679

3.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

4.  Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.

Authors:  Pulak Ranjan Nath; Dipasmita Pal-Nath; Ajeet Mandal; Margaret C Cam; Anthony L Schwartz; David D Roberts
Journal:  Cancer Immunol Res       Date:  2019-07-30       Impact factor: 11.151

5.  CD47 Blockade and Cowpea Mosaic Virus Nanoparticle In Situ Vaccination Triggers Phagocytosis and Tumor Killing.

Authors:  Chao Wang; Nicole F Steinmetz
Journal:  Adv Healthc Mater       Date:  2019-03-06       Impact factor: 9.933

Review 6.  Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling.

Authors:  Sukhbir Kaur; David D Roberts
Journal:  Int J Biochem Cell Biol       Date:  2016-05-06       Impact factor: 5.085

7.  Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.

Authors:  Tadahiko Yanagita; Yoji Murata; Daisuke Tanaka; Sei-Ichiro Motegi; Eri Arai; Edwin Widyanto Daniwijaya; Daisuke Hazama; Ken Washio; Yasuyuki Saito; Takenori Kotani; Hiroshi Ohnishi; Per-Arne Oldenborg; Noel Verjan Garcia; Masayuki Miyasaka; Osamu Ishikawa; Yae Kanai; Takahide Komori; Takashi Matozaki
Journal:  JCI Insight       Date:  2017-01-12

Review 8.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

9.  Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer.

Authors:  Katherine L Cook; David R Soto-Pantoja; Pamela A G Clarke; M Idalia Cruz; Alan Zwart; Anni Wärri; Leena Hilakivi-Clarke; David D Roberts; Robert Clarke
Journal:  Cancer Res       Date:  2016-10-01       Impact factor: 12.701

10.  Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.

Authors:  Albin Jeanne; Camille Boulagnon-Rombi; Jérôme Devy; Louis Théret; Caroline Fichel; Nicole Bouland; Marie-Danièle Diebold; Laurent Martiny; Christophe Schneider; Stéphane Dedieu
Journal:  Clin Exp Metastasis       Date:  2016-06-27       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.